glycine has been researched along with Multiple Sclerosis in 13 studies
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether the naturally occurring amino acid threonine, a potential precursor for glycine biosynthesis in the spinal cord, has an effect on spasticity in multiple sclerosis, 26 ambulatory patients were entered into a randomized crossover trial." | 9.07 | An antispasticity effect of threonine in multiple sclerosis. ( Doolittle, TH; Growdon, J; Hauser, SL; Lehrich, JR; Lopez-Bresnahan, M; Schoenfeld, D; Shahani, B; Shih, VE, 1992) |
| "Acute secondary progressive multiple sclerosis (SPMS) is characterized by escalating neurological disability, with limited disease-modifying therapeutic options." | 5.72 | Guanidinoacetate-creatine in secondary progressive multiple sclerosis: a case report. ( Jezdimirovic, T; Ostojic, J; Ostojic, SM; Stajer, V; Zanini, D, 2022) |
| "To determine whether the naturally occurring amino acid threonine, a potential precursor for glycine biosynthesis in the spinal cord, has an effect on spasticity in multiple sclerosis, 26 ambulatory patients were entered into a randomized crossover trial." | 5.07 | An antispasticity effect of threonine in multiple sclerosis. ( Doolittle, TH; Growdon, J; Hauser, SL; Lehrich, JR; Lopez-Bresnahan, M; Schoenfeld, D; Shahani, B; Shih, VE, 1992) |
| "The encephalitogenic epitope P81-100 from mouse myelin basic protein was used to generate two simplified derivatives with glycine substitutions in alternating positions which were tested for their biological activity in a murine model of multiple sclerosis, experimental autoimmune encephalomyelitis." | 3.70 | Prevention of experimental autoimmune encephalomyelitis by encephalitogenic epitope sequence simplified derivatives. ( Fassina, G; Ippolito, A; Marino, M; Ruvo, M; Scarallo, A; Volpe, S, 2000) |
| "Acute secondary progressive multiple sclerosis (SPMS) is characterized by escalating neurological disability, with limited disease-modifying therapeutic options." | 1.72 | Guanidinoacetate-creatine in secondary progressive multiple sclerosis: a case report. ( Jezdimirovic, T; Ostojic, J; Ostojic, SM; Stajer, V; Zanini, D, 2022) |
| "Taurine levels were significantly lower in encephalitis patients than in the other groups (p = 0." | 1.30 | Does glutamate mediate brain damage in acute encephalitis? ( Hokkanen, L; Launes, J; Lindsberg, PJ; Sirén, J; Viinikka, L, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (30.77) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Ostojic, SM | 1 |
| Ostojic, J | 1 |
| Zanini, D | 1 |
| Jezdimirovic, T | 1 |
| Stajer, V | 1 |
| Ďurfinová, M | 1 |
| Bartová, R | 1 |
| Orešanská, K | 1 |
| Turecký, L | 1 |
| Procházková, Ľ | 1 |
| Petrleničová, D | 1 |
| Líška, B | 1 |
| Ruprecht, K | 1 |
| Wunderlich, B | 1 |
| Gieß, R | 1 |
| Meyer, P | 1 |
| Loebel, M | 1 |
| Lenz, K | 1 |
| Hofmann, J | 1 |
| Rosche, B | 1 |
| Wengert, O | 1 |
| Paul, F | 1 |
| Reimer, U | 1 |
| Scheibenbogen, C | 1 |
| Carmans, S | 1 |
| Hendriks, JJ | 1 |
| Thewissen, K | 1 |
| Van den Eynden, J | 1 |
| Stinissen, P | 1 |
| Rigo, JM | 1 |
| Hellings, N | 1 |
| Ivanova, EM | 1 |
| Barabanova, MA | 1 |
| Muzlaev, GG | 1 |
| Petropavlovskaia, TA | 1 |
| Stoianova, OV | 1 |
| GEORGI, F | 1 |
| BEUTHIEN, A | 1 |
| Kroner, A | 1 |
| Vogel, F | 1 |
| Kolb-Mäurer, A | 1 |
| Kruse, N | 1 |
| Toyka, KV | 1 |
| Hemmer, B | 1 |
| Rieckmann, P | 1 |
| Mäurer, M | 1 |
| Westall, FC | 1 |
| Hawkins, A | 1 |
| Ellison, GW | 1 |
| Myers, LW | 1 |
| Launes, J | 1 |
| Sirén, J | 1 |
| Viinikka, L | 1 |
| Hokkanen, L | 1 |
| Lindsberg, PJ | 1 |
| Marino, M | 1 |
| Ippolito, A | 1 |
| Ruvo, M | 1 |
| Scarallo, A | 1 |
| Volpe, S | 1 |
| Fassina, G | 1 |
| Hauser, SL | 1 |
| Doolittle, TH | 1 |
| Lopez-Bresnahan, M | 1 |
| Shahani, B | 1 |
| Schoenfeld, D | 1 |
| Shih, VE | 1 |
| Growdon, J | 1 |
| Lehrich, JR | 1 |
| Khokhlov, AP | 1 |
| Zavalishin, IA | 1 |
| Savchenko, IuN | 1 |
| Dziuba, AN | 1 |
| Rieder, HP | 1 |
| Wüthrich, R | 1 |
| Ritzel, G | 1 |
1 trial available for glycine and Multiple Sclerosis
| Article | Year |
|---|---|
An antispasticity effect of threonine in multiple sclerosis.
Topics: Adult; Female; Glycine; Humans; Male; Multiple Sclerosis; Muscle Spasticity; Placebos; Threonine | 1992 |
12 other studies available for glycine and Multiple Sclerosis
| Article | Year |
|---|---|
Guanidinoacetate-creatine in secondary progressive multiple sclerosis: a case report.
Topics: Creatine; Female; Glycine; Humans; Magnetic Resonance Spectroscopy; Middle Aged; Multiple Sclerosis; | 2022 |
Increased glycine levels in cerebrospinal fluid of patients with multiple sclerosis.
Topics: Animals; Glycine; Humans; Multiple Sclerosis | 2018 |
Multiple sclerosis: the elevated antibody response to Epstein-Barr virus primarily targets, but is not confined to, the glycine-alanine repeat of Epstein-Barr nuclear antigen-1.
Topics: Adult; Alanine; Antibody Formation; Antigens, Viral; Epitopes; Epstein-Barr Virus Infections; Epstei | 2014 |
The inhibitory neurotransmitter glycine modulates macrophage activity by activation of neutral amino acid transporters.
Topics: Amino Acid Transport Systems, Neutral; Animals; Biotransformation; Cell Proliferation; Cell Survival | 2010 |
[Amino acids content in the blood serum of patients with multiple sclerosis].
Topics: Adult; Aspartic Acid; Chromatography, Ion Exchange; Female; Glutamic Acid; Glycine; Humans; Male; Mu | 2012 |
[Multiple sclerosis; pathogenic considerations and therapeutic possibilities].
Topics: Glycine; Humans; Liver Diseases; Multiple Sclerosis | 1955 |
Impact of the Asp299Gly polymorphism in the toll-like receptor 4 (tlr-4) gene on disease course of multiple sclerosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspartic Acid; Cells, Cultured; Cytokines; Disease Progr | 2005 |
Abnormal glutamic acid metabolism in multiple sclerosis.
Topics: Female; Glutamates; Glycine; Humans; Male; Multiple Sclerosis; Recurrence; Tryptophan | 1980 |
Does glutamate mediate brain damage in acute encephalitis?
Topics: Adult; Aged; Amino Acids; Brain; Cerebral Infarction; Encephalitis; Encephalitis, Viral; Female; Glu | 1998 |
Prevention of experimental autoimmune encephalomyelitis by encephalitogenic epitope sequence simplified derivatives.
Topics: Animals; Antigenic Variation; Encephalomyelitis, Autoimmune, Experimental; Epitopes; Glycine; Histoc | 2000 |
[Disorders of formaldehyde metabolism and its metabolic precursors in patients with multiple sclerosis].
Topics: Adolescent; Adult; Betaine; Enzyme Activation; Female; Formaldehyde; Glycine; Humans; Leucyl Aminope | 1989 |
[Studies on the seasonal incidence of multiple sclerosis. II. The seasonal variability of biological data].
Topics: Antibodies; Cerebrospinal Fluid; Cholesterol; Glycine; Humans; Liver Function Tests; Multiple Sclero | 1968 |